» Articles » PMID: 36277506

Advances of Engineered Extracellular Vesicles-based Therapeutics Strategy

Overview
Date 2022 Oct 24
PMID 36277506
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular vesicles (EVs) are a heterogeneous population of lipid bilayer membrane-bound vesicles which encapsulate bioactive molecules, such as nucleic acids, proteins, and lipids. They mediate intercellular communication through transporting internally packaged molecules, making them attractive therapeutics carriers. Over the last decades, a significant amount of research has implied the potential of EVs servings as drug delivery vehicles for nuclear acids, proteins, and small molecular drugs. However, several challenges remain unresolved before the clinical application of EV-based therapeutics, including lack of specificity, stability, biodistribution, storage, large-scale manufacturing, and the comprehensive analysis of EV composition. Technical development is essential to overcome these issues and enhance the pre-clinical therapeutic effects. In this review, we summarize the current advancements in EV engineering which demonstrate their therapeutic potential.

Citing Articles

Cell-free osteoarthritis treatment with dual-engineered chondrocyte-targeted extracellular vesicles derived from mechanical loading primed mesenchymal stem cells.

Wang P, Zhao H, Chen W, Guo Y, Zhang S, Xing X J Tissue Eng. 2025; 16:20417314241312563.

PMID: 39926048 PMC: 11806476. DOI: 10.1177/20417314241312563.


Extracellular Vesicles as Tools for Crossing the Blood-Brain Barrier to Treat Lysosomal Storage Diseases.

Lerussi G, Villagrasa-Araya V, Molto-Abad M, Del Toro M, Pintos-Morell G, Seras-Franzoso J Life (Basel). 2025; 15(1).

PMID: 39860010 PMC: 11766495. DOI: 10.3390/life15010070.


Engineering extracellular vesicles for targeted therapeutics in cardiovascular disease.

Fu E, Pan K, Li Z Front Cardiovasc Med. 2025; 11:1503830.

PMID: 39749310 PMC: 11693616. DOI: 10.3389/fcvm.2024.1503830.


Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics.

Li X, Wei Y, Zhang Z, Zhang X Extracell Vesicles Circ Nucl Acids. 2024; 5(1):44-63.

PMID: 39698409 PMC: 11648408. DOI: 10.20517/evcna.2023.58.


Basic Guide for Approaching Drug Delivery with Extracellular Vesicles.

Brezgin S, Danilik O, Yudaeva A, Kachanov A, Kostyusheva A, Karandashov I Int J Mol Sci. 2024; 25(19).

PMID: 39408730 PMC: 11476574. DOI: 10.3390/ijms251910401.


References
1.
Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuchel R, Kiessling F . Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325. PMC: 7115878. DOI: 10.1016/j.addr.2019.01.005. View

2.
Wang M, Altinoglu S, Takeda Y, Xu Q . Integrating Protein Engineering and Bioorthogonal Click Conjugation for Extracellular Vesicle Modulation and Intracellular Delivery. PLoS One. 2015; 10(11):e0141860. PMC: 4631329. DOI: 10.1371/journal.pone.0141860. View

3.
Stam J, Bartel S, Bischoff R, Wolters J . Isolation of extracellular vesicles with combined enrichment methods. J Chromatogr B Analyt Technol Biomed Life Sci. 2021; 1169:122604. DOI: 10.1016/j.jchromb.2021.122604. View

4.
Takahashi Y, Nishikawa M, Shinotsuka H, Matsui Y, Ohara S, Imai T . Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol. 2013; 165(2):77-84. DOI: 10.1016/j.jbiotec.2013.03.013. View

5.
Erdbrugger U, Blijdorp C, Bijnsdorp I, Borras F, Burger D, Bussolati B . Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. J Extracell Vesicles. 2021; 10(7):e12093. PMC: 8138533. DOI: 10.1002/jev2.12093. View